头孢哌酮与莫西沙星治疗肺部感染的疗效对比  

Cefoperazone vs. Moxifloxacin in the Treatment of Pulmonary Infection

作　　者：杨炜[1] 陈力[2] 

机构地区：[1]成都市第六人民医院呼吸内科,成都市610051 [2]成都铁路中心医院老年科,成都市610081

出　　处：《中国医院用药评价与分析》2009年第7期540-541,共2页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:比较头孢哌酮与莫西沙星治疗肺部感染的疗效及其安全性。方法:共选入肺部感染住院患者120例,随机分为两组,其中应用头孢哌酮治疗60例、莫西沙星治疗60例。结果:头孢哌酮组有效率86.7%,莫西沙星组有效率93.3%;对致病菌株的清除率分别为83%和90.8%;不良反应发生率分别为5%与3.3%,两者临床疗效无明显差异(P>0.05)。结论:头孢哌酮与莫西沙星都是安全有效治疗肺部感染的药物。OBJECTIVE：To evaluate the therapeutic efficacy and adverse reactions of cefoperazone vs.moxifloxacin for pulmonary infection.METHODS：120 inpatients with pulmonary infection were randomly assigned to receive cefoperazone（n=60） or moxifloxacin（n=60）.RESULTS：There were no significant differences between the cefoperazone group and the moxifloxacin group in clinical efficacy（P〉0.05）（effective rate：86.7% vs.93.3%;bacterial clearance rate：83% vs.90.8%;incidence of adverse reactions：5% vs.3.3%） CONCLUSION：Both cefoperazone and moxifloxacin are safe and effective for patients with pulmonary infection.

关 键 词：头孢哌酮 莫西沙星 肺部感染 临床疗效 安全性 

分 类 号：R978.1[医药卫生—药品]